Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® CRM Announces European Launch of New Tablet Programmer for Implantable Cardiac Devices


Clamart, France – January 21st, 2018 - MicroPort® CRM (a business unit of MicroPort Scientific Corporation), is pleased to announce the European launch of Smart Touch™, a totally new tablet-based programmer.
Pacemakers, implantable defibrillators and cardiac resynchronization devices require individual programming at implant and during follow-up visits, enabling the device settings to be regularly adapted and tailored to suit the needs of each patient.
The programmer is used by the physician or nurse to interact with the device via inductive telemetry or RF wireless connectivity. Up till now, programmers have been cumbersome, heavy pieces of equipment requiring hospital trolleys to transport them, limiting efficiency and mobility.
To enhance mobility and flexibility, the Smart Touch™ programmer has a light-weight tablet design. Physicians can use the Smart Touch™ tablet either directly in its docking station or in a hand-held fashion at the patient's bedside. The new battery-powered tablet removes unnecessary power cables providing much better freedom and mobility to physicians as well as an improved follow-up experience for patients.
Smart Touch™ also features Bluetooth technology to facilitate wireless connection with accessories such as printers or ECG equipment for greater efficiency and speed.
"I am impressed by this new tablet programmer," commented Dr. Vincent Ganière of the Hôpital Saint Loup, the first user of Smart Touch™ in Switzerland. "It's the first time I've seen a solution like this, it's very intuitive."
"With the Smart Touch™ tablet programmer we are providing our customers with a high-tech, modern tool that is more in line with their needs, facilitating programming and speeding up the follow-up of our implantable devices. Our goal with Smart Touch™ is to bring more comfort into daily practice and enhance the overall follow-up experience for physicians and patients alike", commented Benoit Clinchamps, President of MicroPort® CRM.


About MicroPort® CRM
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort® CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort® CRM is part of MicroPort Scientific Corporation.
For more information visit

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957


[Prev]:MicroPort® Firehawk® Stent Pivotal Study TARGET DAPT Trial Launched at Zhongshan Hospital Affiliated to Fudan University and Completed First Enrollment
[Next]:MicroPort® CRM Announces European Launch of World's Smallest 1.5T & 3T MRI Conditional Pacemaker Portfolio*